• Twitter Clean
  • w-facebook

DRW (Europe) Ltd

Suite 12, Science Village

Chesterford Research Park

Little Chesterford, CB10 1XL

UK

© 2019 DRW Ltd.

DRW (US) Ltd

845 Embedded Way

Suite 150

San Jose, CA 95138

USA

SAMBA

Point-of-care diagnostics for the real world

 

The SAMBA (Simple AMplification Based Assay) system is an innovative nucleic acid-based rapid test particularly suitable for HIV diagnostics. A key feature is its ability to provide a “test and treat” facility at the point-of-care and, critically, to do so in resource-limited areas where reliable diagnosis and monitoring would otherwise be unavailable.  

 

SAMBA offers:

  • Early infant diagnosis

  • Acute infection diagnosis

  • Viral load for therapy monitoring

 

The SAMBA platform offers qualitative or semi-quantitative detection of analytes such as HIV RNA in plasma samples for use as an aid in the diagnosis and monitoring of HIV infection especially in babies and in anti-retroviral therapy monitoring. 

 

SAMBA is delivered  through two discrete assay instruments: SAMBA I and SAMBA II. Both platforms use the same chemistry but are designed to meet different operational needs.  

 

Assays in development for the SAMBA platform include tests for hepatitis B and C, influenza A and B, as well as a duplex test for chlamydia and gonorrhea. 

PERFORMANCE SPECIFICATIONS:

 

Whole Blood Qualitative test for Early Infant and Acute Infection Diagnosis

 

  • Sensitivity: 98.6%

  • Specificity: 99.8%

 

Plasma Semi-Quantitative test:

  • Concordance: 96-99% compared to centralised testing